









Mercado
/
Acciones
/
nasdaq-cdtx
/

Cidara Therapeutics Inc

CDTX

106.670USD

+2.880+2.77%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

3.13BCap. mercado

PérdidaP/E TTM



Cidara Therapeutics Inc

106.670

+2.880+2.77%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Cidara Therapeutics Inc Compañía

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Información de Cidara Therapeutics Inc



Símbolo de cotizaciónCDTX

Nombre de la empresaCidara Therapeutics Inc

Fecha de salida a bolsaApr 15, 2015

Director ejecutivoDr. Jeffrey L. (Jeff) Stein, Ph.D.

Número de empleados38

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 15

Dirección6310 Nancy Ridge Dr Ste 101

CiudadSAN DIEGO

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal92121-3209

Teléfono18587526170

Sitio Webhttps://www.cidara.com/

Símbolo de cotizaciónCDTX

Fecha de salida a bolsaApr 15, 2015

Director ejecutivoDr. Jeffrey L. (Jeff) Stein, Ph.D.

Ejecutivos de Cidara Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

Mr. Ryan Spencer

Independent Director

Dr. Bonnie Bassler, Ph.D.

Independent Director

Ms. Chrysa Mineo

Independent Director

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

Mr. Brian Ritchie

Investor Relations

Mr. Theodore R. (Ted) Schroeder

Independent Director

Mr. Shane Ward

Chief Operating Officer, Chief Legal Officer, Company Secretary

Dr. Josh Resnick, M.D., J.D.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

Mr. Ryan Spencer

Independent Director

Dr. Bonnie Bassler, Ph.D.

Independent Director

Ms. Chrysa Mineo

Independent Director

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: vie., 31 de oct

Accionistas

Tipos de accionistas

Accionistas

Proporción

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Otro

68.40%

Accionistas

Proporción

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Otro

68.40%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

40.25%

Investment Advisor

26.13%

Venture Capital

22.74%

Investment Advisor/Hedge Fund

18.53%

Research Firm

4.33%

Individual Investor

0.89%

Pension Fund

0.09%

Bank and Trust

0.08%

Private Equity

0.06%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

223

28.87M

92.92%

+14.12M

2025Q2

140

15.92M

78.58%

+7.99M

2025Q1

124

10.47M

53.54%

+2.71M

2024Q4

122

7.70M

70.35%

+1.07M

2024Q3

109

4.49M

61.04%

+771.77K

2024Q2

109

1.90M

39.70%

+56.88K

2024Q1

108

1.55M

384.06%

-209.94K

2023Q4

111

1.70M

37.69%

-299.58K

2023Q3

119

1.90M

42.77%

-451.34K

2023Q2

126

1.95M

43.98%

-451.51K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

RA Capital Management, LP

3.37M

13.27%

Aug 07, 2025

Bain Capital Life Sciences Investors, LLC

2.50M

9.86%

+1.80M

+255.68%

Jun 30, 2025

Point72 Asset Management, L.P.

1.53M

6.03%

+528.52K

+52.88%

Jun 30, 2025

Vivo Capital, LLC

1.31M

5.17%

+627.15K

+91.65%

Jun 30, 2025

The Vanguard Group, Inc.

966.71K

3.81%

+457.13K

+89.71%

Jun 30, 2025

BVF Partners L.P.

786.39K

3.1%

-138.25K

-14.95%

Jun 30, 2025

Commodore Capital LP

1.18M

4.63%

+1.18M

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.13M

4.45%

+1.13M

Jul 23, 2025

Adage Capital Management, L.P.

1.10M

4.34%

+110.00K

+11.11%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.02M

4.03%

+974.57K

+2030.95%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Invesco Dorsey Wright Healthcare Momentum ETF

3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

1.39%

SPDR S&P Biotech ETF

0.77%

Direxion Daily S&P Biotech Bull 3X Shares

0.41%

Even Herd Long Short ETF

0.39%

iShares Micro-Cap ETF

0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

0.25%

Vanguard US Momentum Factor ETF

0.23%

iShares Russell 2000 Value ETF

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.09%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporción1.39%

SPDR S&P Biotech ETF

Proporción0.77%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.41%

Even Herd Long Short ETF

Proporción0.39%

iShares Micro-Cap ETF

Proporción0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

Proporción0.25%

Vanguard US Momentum Factor ETF

Proporción0.23%

iShares Russell 2000 Value ETF

Proporción0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporción0.09%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Fecha

Tipo

Relación

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

KeyAI

